Tick-borne viral encephalitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:31:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Tick-borne viral encephalitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Testing Remdesivir in Hospitalized Adult Patients with Tick-Borne Encephalitis to Measure Effects on Brain Cell Damage https://clinicaltrials.eu/trial/testing-remdesivir-in-hospitalized-adult-patients-with-tick-borne-encephalitis-to-measure-effects-on-brain-cell-damage/ Thu, 30 Apr 2026 13:08:39 +0000 https://clinicaltrials.eu/trial/testing-remdesivir-in-hospitalized-adult-patients-with-tick-borne-encephalitis-to-measure-effects-on-brain-cell-damage/ This study examines Tick-Borne Encephalitis, which is an infection caused by a virus transmitted through tick bites that affects the brain and nervous system. The study will test whether remdesivir, an antiviral medication, can help reduce damage to nerve cells in patients with this infection. Participants will receive either remdesivir or placebo through an intravenous infusion, which means the medication is given directly into a vein. An additional substance called mannitol, which belongs to a group called electrolytes, will also be used as part of the infusion solution. The purpose of the study is to evaluate whether remdesivir can reduce nerve cell injury during the infection, as measured by a substance in the blood called neurofilament light chain.

The treatment period will last up to 10 days, with participants receiving a daily dose of up to 200 milligrams of the medication. The total amount of medication given over the treatment period will not exceed 1100 milligrams. During the study, various tests and assessments will be performed at different time points, including blood samples, thinking and memory tests, questionnaires about fatigue and quality of life, and neurological examinations. Some participants may also provide samples of cerebrospinal fluid, which is the liquid surrounding the brain and spinal cord, as well as urine and saliva samples.

Participants will be followed for up to one year after starting treatment. During this time, they will undergo cognitive testing to assess memory, learning, attention, and thinking skills at weeks 12, 26, and 52. The study will also measure fatigue levels, pain scores, overall health status, and various biological markers in blood and other body fluids. Additional tests will examine the presence of the virus, antibody responses, and other factors that might influence how well the treatment works. The study will compare results between those receiving remdesivir and those receiving placebo to determine if the medication is effective in treating this infection.

]]>